The U.S. Food and Drug Administration (FDA) issued a safety communicationexternal icon warning test users and caregivers, health care providers, and testing program organizers to stop using the Innova SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic use. FDA has significant concerns that the performance of the test has not been adequately established, and its use could present a health risk. Additionally, FDA has not authorized, cleared, or approved the test for commercial distribution or use in the United States, as required by law. The FDA has classified the recall of this test as a Class I recallexternal icon, the most serious type of recall.

The Innova SARS-CoV-2 Antigen Rapid Qualitative Test is also distributed under the following names:

Innova COVID-19 Self-Test Kit (3T Configuration)

Innova SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration)

Innova SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration)